ArticleHeliyon2024

Gilteritinib overcomes primary resistance to venetoclax in a patient with FLT3 wild-type refractory/relapsed AML: Case report and exploration of possible mechanisms.

Man Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.